RXI Pharma (RXII) Posts Mixed Q3 Results

RXI Pharma (NASDAQ: RXII) reported Q3 EPS of ($0.17), $0.05 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $16 thousand versus the consensus estimate of $20 thousand.

For earnings history and earnings-related data on RXI Pharma (RXII) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Vivos Therapeutics posts 35% revenue gain but widens net loss
• Diana Shipping withdraws bid to acquire Genco Shipping